<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Durcan E</submitter><funding>Bilimsel Araştirma Projeleri Birimi, Istanbul Üniversitesi</funding><pagination>236-246</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9060072</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(4)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The aim of this study was to investigate the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on the glomerulus through the evaluation of podocyturia in patients with diabetic kidney disease (DKD).&lt;h4>Methods&lt;/h4>The study population was composed of 40 male patients with type 2 diabetes mellitus; 22 of them received SGLT2i (SGLT2i group), and the others who did not were the control. The DKD-related parameters of patients were monitored before SGLT2i initiation, and then in the third and sixth month of the follow-up period. Patients' demographic, clinical, laboratory, and follow-up data were obtained from medical charts. Microalbuminuria was measured in 24-h urine. The number of podocytes in the urine was determined by immunocytochemical staining of two diffe</pubmed_abstract><journal>Journal of diabetes</journal><pubmed_title>Effects of SGLT2 inhibitors on patients with diabetic kidney disease: A preliminary study on the basis of podocyturia.</pubmed_title><pmcid>PMC9060072</pmcid><funding_grant_id>33562</funding_grant_id><pubmed_authors>Saygi HI</pubmed_authors><pubmed_authors>Bakir A</pubmed_authors><pubmed_authors>Sahin S</pubmed_authors><pubmed_authors>Karaca C</pubmed_authors><pubmed_authors>Durcan E</pubmed_authors><pubmed_authors>Dincer MT</pubmed_authors><pubmed_authors>Gonen MS</pubmed_authors><pubmed_authors>Sulu C</pubmed_authors><pubmed_authors>Ozkan S</pubmed_authors><pubmed_authors>Trabulus S</pubmed_authors><pubmed_authors>Guzel E</pubmed_authors><pubmed_authors>Seyahi N</pubmed_authors><pubmed_authors>Korkmaz OP</pubmed_authors><pubmed_authors>Ozkaya HM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effects of SGLT2 inhibitors on patients with diabetic kidney disease: A preliminary study on the basis of podocyturia.</name><description>&lt;h4>Background&lt;/h4>The aim of this study was to investigate the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on the glomerulus through the evaluation of podocyturia in patients with diabetic kidney disease (DKD).&lt;h4>Methods&lt;/h4>The study population was composed of 40 male patients with type 2 diabetes mellitus; 22 of them received SGLT2i (SGLT2i group), and the others who did not were the control. The DKD-related parameters of patients were monitored before SGLT2i initiation, and then in the third and sixth month of the follow-up period. Patients' demographic, clinical, laboratory, and follow-up data were obtained from medical charts. Microalbuminuria was measured in 24-h urine. The number of podocytes in the urine was determined by immunocytochemical staining of two diffe</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2025-04-18T13:15:37.671Z</modification><creation>2025-04-06T22:49:14.028Z</creation></dates><accession>S-EPMC9060072</accession><cross_references><pubmed>35229458</pubmed><doi>10.1111/1753-0407.13261</doi></cross_references></HashMap>